XRAY

DENTSPLY SIRONA Inc. 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026, and the six months ended on that date. DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company is a large accelerated filer with shares traded on the Nasdaq under the symbol XRAY.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to profitability in Q2 2026 ($37M net income) compared to a net loss of $45M in Q2 2025. This improvement is largely due to the absence of a $235M goodwill and intangible asset impairment charge recorded in Q2 2025.
• Revenue Decline: Net sales decreased 4.1% year-over-year in Q2 2026 and 2.1% for the six-month period. On a constant currency basis, the decline was more pronounced (6.3% for Q2), driven by lower volumes in the Americas (notably the absence of Byte business sales) and unfavorable pricing in EMEA and APAC.
• Restructuring Costs: Restructuring and other costs increased significantly to $69M for the six months ended June 30, 2026, compared to $13M in the prior year period. This is primarily due to the "2026 Plan" approved in February 2026, targeting $120M in annualized cost savings.
• Tariff Refunds: The company received approximately $44M in refunds for prior U.S. tariff payments during the second quarter of 2026, which favorably impacted operating income and cash flow.
• Dividend Suspension: The Board eliminated the declaration of quarterly dividends starting in the quarter ended March 31, 2026.

Guidance, Outlook, and Risks

• Outlook: Management expects R&D investment to be approximately 5% of annual net sales in 2026. Capital expenditures are estimated at $140M to $160M for the full year, focusing on supply chain upgrades, DS Core enhancements, and a new global ERP system.
• Restructuring Plan: The 2026 Plan expects total non-recurring charges of $60M to $65M, with the majority expensed and paid in 2026 and 2027.
• Risks and Contingencies:
  • Legal Proceedings: The company faces multiple securities class actions and derivative suits alleging misrepresentations regarding revenue recognition (distributor rebates) and the Byte acquisition. While a liability has been accrued with an offsetting insurance receivable, the outcome remains uncertain.
  • Geopolitical & Trade: Ongoing conflicts in the Middle East and Russia-Ukraine, along with evolving U.S. tariff policies, pose risks to supply chains and demand. The company holds $57M in cash in Russia which is difficult to repatriate.
  • Asset Impairment: While no impairment was recognized in the April 2026 annual test, future declines in fair value or equity valuations could trigger material charges.

Investor Verification Checklist

• Byte Business Impact: Verify the extent of the revenue decline in the Orthodontic and Implant Solutions segment specifically attributable to the absence of Byte sales in 2026.
• Restructuring Execution: Monitor the progress of the 2026 Plan to ensure the projected $120M in annualized cost savings are realized without further unexpected charges.
• Legal Exposure: Review the status of the consolidated securities litigation and derivative suits to assess potential future liabilities beyond the currently accrued amounts.
• Cash Flow Sustainability: Confirm that operating cash flow remains robust despite the suspension of dividends and ongoing capital expenditures for the new ERP system.
• Tariff Policy Volatility: Assess the sustainability of the $44M tariff refund benefit and the potential for future tariff costs to impact margins.